These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27581054)

  • 1. Can lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease?
    Cheng BC; Chen YC
    J Investig Med; 2017 Jan; 65(1):53-56. PubMed ID: 27581054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.
    Cheng BC; Chen YC
    Clin Rheumatol; 2017 Apr; 36(4):929-932. PubMed ID: 27757701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.
    Mochizuki T; Yano K; Ikari K; Kawakami K; Hiroshima R; Koenuma N; Ishibashi M; Momohara S
    J Bone Miner Metab; 2018 Jul; 36(4):431-438. PubMed ID: 28681148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
    Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
    Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.
    Kobel C; Frey D; Graf N; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2019; 44(5):1285-1293. PubMed ID: 31614356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between mild-to-moderate chronic kidney disease and decreased bone mineral density in Chinese adult population.
    Kong X; Tang L; Ma X; Liu W; Wang Z; Cui M; Xu D
    Int Urol Nephrol; 2015 Sep; 47(9):1547-53. PubMed ID: 26265108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group.
    Fassio A; Andreola S; Gatti D; Pollastri F; Gatti M; Fabbrini P; Gambaro G; Ferraro PM; Caletti C; Rossini M; Viapiana O; Bixio R; Adami G
    Calcif Tissue Int; 2024 Jul; 115(1):23-30. PubMed ID: 38730099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients
.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Clin Nephrol; 2019 Jul; 92(1):1-8. PubMed ID: 30990412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Density, Microarchitecture, and Tissue Quality Long-term After Kidney Transplant.
    Pérez-Sáez MJ; Herrera S; Prieto-Alhambra D; Nogués X; Vera M; Redondo-Pachón D; Mir M; Güerri R; Crespo M; Díez-Pérez A; Pascual J
    Transplantation; 2017 Jun; 101(6):1290-1294. PubMed ID: 27467533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and renal outcomes of low bone mineral density in patients with non-dialysis chronic kidney disease.
    Hyun YY; Lee KB; Han SH; Choi KH; Park HC; Oh YK; Park SK; Oh KH; Ahn C;
    Osteoporos Int; 2020 Dec; 31(12):2373-2382. PubMed ID: 32642852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower Serum Creatinine Is Associated with Low Bone Mineral Density in Subjects without Overt Nephropathy.
    Huh JH; Choi SI; Lim JS; Chung CH; Shin JY; Lee MY
    PLoS One; 2015; 10(7):e0133062. PubMed ID: 26207750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density following long-term simultaneous pancreas-kidney transplantation.
    Rocha A; Martins LS; Malheiro J; Dores J; Santos C; Henriques C
    J Bone Miner Metab; 2016 Mar; 34(2):209-15. PubMed ID: 25837429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.
    Kim CS; Bae EH; Ma SK; Han SH; Choi KH; Lee J; Chae DW; Oh KH; Ahn C; Kim SW;
    PLoS One; 2016; 11(11):e0166792. PubMed ID: 27855207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.
    Kim JT; Kim YM; Jung KY; Choi H; Lee SY; Kim HJ
    Korean J Intern Med; 2024 Jan; 39(1):148-159. PubMed ID: 38145616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.